湖南景峰医药股份有限公司关于公司股价可能较大幅度向下除权的第二次风险提示公告

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. is undergoing a restructuring process, which has led to a significant risk of downward adjustment in its stock price due to a capital reserve increase plan that will double the total share count [2][3][4]. Group 1: Stock Price Adjustment Risk - The company plans to implement a capital reserve increase by converting its capital reserve into shares at a ratio of 1:1, resulting in an increase of total shares from 879,774,351 to 1,759,548,702 [3]. - The newly issued shares will not be distributed to existing shareholders but will be acquired by restructuring investors, with funds used for bankruptcy costs, debt repayment, and working capital [3]. - The reference price for the stock's ex-rights adjustment will be calculated based on the average price of 2.34 yuan per share, with potential adjustments depending on the stock's closing price on the registration date [4]. Group 2: Restructuring Plan Execution - The Changde Intermediate People's Court has approved the company's restructuring plan and terminated the restructuring process, moving into the execution phase [2][5]. - If the company fails to execute the restructuring plan, it may face bankruptcy, which could lead to the termination of its stock listing [5]. - The company has reported negative net profits for the years 2022, 2023, and 2024, raising concerns about its ongoing viability and compliance with stock listing rules [6].